18 and older, any sex, with Burnout, Caregiver or Burnout, Professional. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Montgomery-Asberg Depression Rating ScalePrimary· 4-weeks post psilocybin-assisted psychotherapy
Assesses symptoms of depression (clinician-assessed): minimum score 0, max 60; higher score indicates more severe symptoms
Group
Value
95% CI
Psilocybin Arm
21.33
± 7.84
Placebo
9.33
± 7.32
Montgomery-Asberg Depression Rating ScaleSecondary· 24 weeks post-psilocybin in the randomized phase psilocybin arm
Assesses symptoms of depression (clinician-assessed): minimum score 0, max 60; higher score indicates more severe symptoms
Group
Value
95% CI
Psilocybin Arm
3.67
± 4.48
PTSD Checklist for DSM-5 (PCL5)Secondary· 4 weeks post-psilocybin or placebo session
Assesses symptoms of post-traumatic stress disorder; minimum score 0, max 80; higher scores indicate more severe symptoms of PTSD
Group
Value
95% CI
Psilocybin Arm
16.67
± 15.04
Placebo
6.74
± 10.69
Sponsor's own description
This study aims to investigate the effects of a single dose of psilocybin, delivered in the contextof pre- and post-dose psychotherapy, on symptoms of depression and burnout suffered by healthcare clinicians as a result of frontline work in the COVID pandemic.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07251491 — Psilocybin to Treat Depression in Spinal Cord Injury
· Phase 1, PHASE2
· not yet recruiting
NCT06988319 — Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study
· Phase 1
· not yet recruiting
NCT07490353 — Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects
· Phase 1
· recruiting
Other recruiting trials for Burnout, Caregiver
Currently open trials in the same condition.
NCT05884073 — Exercise for Oncology Care Professionals
· NA
· recruiting
NCT05677997 — Evaluating the Impact of Resource Navigators to Support LTC and RH Staff During and Beyond COVID-19
· NA
· recruiting
NCT05833269 — Intercare, Mindfulness and Compassion Based Intervention for Parental Burnout
· NA
· active not recruiting
NCT05416216 — Wellbeing of the ECE Workforce in Low-resourced Locations
· NA
· active not recruiting
Other University of Washington trials
Trials by the same sponsor.
NCT07430852 — Inherited and Environmental Risks Acting on Body Weight
· NA
· not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc
· Phase 2
· not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn
· NA
· not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
· Phase 2
· not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 18 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05163496.